Tirapazamine

SKU: orb1222431

Description

Trapazamine, also known as SR-4233,DNA-damaging drug potentially for the treatment of cervical carcinoma, head and neck cancer. Tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors. Cells in these regions are resistant to killing by radiotherapy and most anticancer drugs. Thus the combination of tirapazamine with conventional anticancer treatments is particularly effective.(In Vitro):Tirapazamine (SR259075) is the optimal drug for combination therapy using Pba.(In Vivo):Tirapazamine (SR259075) (1mg; intravenously injected; twice at a 24-h interval) shows a synergetic effect to kill tumor cells because TPZ was activated under the hypoxic conditions that originated from the PDT with Pba and laser irradiation.\n.

Key Properties

• CAS Number: 27314-97-2
• MW: 178.15
• Purity: >98% (HPLC)
• Formula: C₇H₆N₄O₂
• SMILES: Nc1nn(=O)c2ccccc2n1=O
• Target: Others
• Solubility: DMSO : ≥ 39 mg/m; 218.92 mM

Bioactivity

• In Vivo:
  Tirapazamine (SR259075) (1mg; intravenously injected; twice at a 24-h interval) shows a synergetic effect to kill tumor cells because TPZ was activated under the hypoxic conditions that originated from the PDT with Pba and laser irradiation. Animal model: C3H/HeN mice. Dosage: 1mg. Administration: Tirapazamine (1mg; intravenously injected; twice at a 24-h interval). Result: Suppressed the tumors of mice by using laser irradiation.
  Read more...
• In Vitro:
  Tirapazamine (SR259075) is the optimal drug for combination therapy using Pba. Cell Viability Assay Cell line: SCC7 cells. Concentration: 1 mg. Incubation time: 24 h. Result: Showed synergism with Pba at ED50, ED90 and ED95.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Tirapazamine | Tirazone | SR 4233 | SR-4233 | WIN 59075

Quick Database Links

Gene Symbol

Others